Do Private Pay Patients Pose a Compliance Risk for My Practice

Private pay patients pose a compliance risk that is distinct from, and in some respects greater than, the risk posed by insured patients. The difference lies in the absence of the insurance company oversight mechanisms that, imperfect as they are, provide an independent check on prescribing patterns.

This is not an argument against treating private pay patients. They are a legitimate category of patient whose medical needs are as real as those of insured patients and whose access to healthcare depends on practitioners who will see them. It is an argument for understanding the specific compliance risks that private pay patients create and for implementing the monitoring and documentation practices that manage those risks.

The Absence of Insurance Oversight

Insurance companies and pharmacy benefit managers monitor their members’ prescription histories through utilization review programs. When a member’s opioid prescriptions reach thresholds that the insurer’s algorithms identify as unusual, a prior authorization requirement, a quantity limit, or a utilization review inquiry may follow. These mechanisms are imperfect and are not substitutes for clinical judgment, but they provide an external check on prescribing patterns that is entirely absent for patients who pay out of pocket.

The private pay patient who receives controlled substance prescriptions has no insurer reviewing the prescribing frequency or the quantity dispensed. The PDMP provides monitoring if the prescribing practitioner or the dispensing pharmacy consults it, and if the state’s PDMP is current and comprehensive. Beyond the PDMP, the monitoring of private pay patients’ prescribing and use is the sole responsibility of the prescribing practitioner.

The Diversion Risk Profile

Patients who seek out private pay practices for controlled substance prescriptions, particularly when insurance coverage is available to them and they are choosing not to use it, present a diversion risk profile that warrants specific clinical attention. The patient who could submit a controlled substance prescription to insurance but who prefers to pay cash may have legitimate reasons for that preference, but the preference itself is an indicator that the prescribing practitioner should document a clinical assessment of.

PDMP consultation for private pay patients is as important as PDMP consultation for insured patients, and in the context of the diversion risk profile associated with private pay controlled substance prescriptions, arguably more important. The private pay patient whose PDMP record shows a recent controlled substance prescription from another provider, who chose to seek a second prescription through a cash-only channel, has generated a pattern that the prescribing practitioner must assess and document before proceeding.

Documentation Requirements

The clinical documentation standard for private pay controlled substance prescriptions must be identical to the standard applied to insured patients. A practice whose medical records for private pay controlled substance patients are consistently less thorough than its records for insured patients has created a compliance disparity that is difficult to explain as anything other than differential standards for different patient categories. That differential is the kind of evidence that investigations characterize as reflecting awareness that the private pay prescriptions required less clinical justification than the insured ones.

DEFENSE TEAM SPOTLIGHT

Todd Spodek

Lead Attorney & Founder

Featured on Netflix's "Inventing Anna," Todd Spodek brings decades of high-stakes criminal defense experience. His aggressive approach has secured dismissals and acquittals in cases others deemed unwinnable.

NY Bar Admitted Multi-State Licensed Federal Courts

Meet the Full Team

The private pay patient is not a compliance risk by virtue of their payment method alone. They are a compliance risk because the absence of insurance oversight places the entire burden of detecting and responding to diversion on the prescribing practitioner and the PDMP. A practice that accepts that burden, exercises it through consistent monitoring and documentation, and maintains the same clinical standards for private pay patients as for insured patients has managed the compliance risk. A practice that accepts the cash without accepting the monitoring responsibility has not.

Risk Stratification for Private Pay Patients

Private pay status should be incorporated into the practice’s risk stratification framework for controlled substance prescribing. A patient who is uninsured because they lack employment or because their employment does not provide insurance presents a different risk profile than a patient who has insurance but specifically seeks a cash-paying practice for controlled substance prescriptions. The risk stratification that identifies the latter as a patient warranting enhanced monitoring, more frequent PDMP consultation, and more thorough clinical documentation has addressed the specific compliance risk that private pay controlled substance prescribing creates.